Source: Targeted Oncology, June 2025
Treatment for symptomatic melanoma brain metastases remains challenging, with limited efficacy from current standard immunotherapies like anti–PD-1 and anti-CTLA4. However, targeted triplet regimens have shown greater promise than doublet regimens in the space, and the randomized phase 2 SWOG S2000 sought to investigate a triplet regimen incorporating BRAF/MEK inhibitors further.
Here, Zeynep Eroglu, MD, discusses the study in an interview with Targeted OncologyTM. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine.